Press Releases
GNS Healthcare and Alliance for Clinical Trials in Oncology Present Results of Causal Modeling that Identifies Clinical and Molecular Drivers of Survival in Colorectal Cancer Patients
Results presented at ASCO 2018 Annual Meeting in Chicago show drivers at baseline allow better risk stratification at initiation of treatment
read moreGNS Healthcare Names Ted Goldstein, Silicon Valley Tech Innovator and Scientific Program Director of Computational Health at UCSF to its Strategic Advisory Board
CAMBRIDGE, Mass.–May 31, 2018 – GNS Healthcare (GNS), a leading precision medicine company, announced the appointment of Dr. Ted Goldstein, Scientific Program Director of Computational Health of University of California, San Francisco, to its Strategic Advisory Board...
read moreGNS Healthcare to Present Results on Prediction of Disease Progression Using AI in NASH Patients at The International Liver Congress™
CAMBRIDGE, Mass.– April 13, 2018– GNS Healthcare (GNS), a leading precision medicine company, will present results from a recent study on Friday, April 13th at the International Liver Congress™ 2018 in Paris. The analysis focused on the progression of Nonalcoholic...
read moreGNS Healthcare Names Patrick Getzen, Chief Data and Analytics Officer of Blue Cross and Blue Shield of North Carolina, to its Strategic Advisory Board
CAMBRIDGE, Mass.– February 6, 2018 – GNS Healthcare (GNS), a leading precision medicine company, announced the appointment of Patrick Getzen, Chief Data and Analytics Officer of Blue Cross and Blue Shield of North Carolina (Blue Cross NC), to its Strategic Advisory...
read moreGNS Healthcare Uses Causal AI to Discover Which Multiple Myeloma Patients Will Have Progression Free Survival Benefit from Stem Cell Treatments
Details of the Discovery Leveraging the Multiple Myeloma Research Foundation CoMMpass Study Presented at 59th Annual ASH Meeting
read moreGNS Healthcare Names Dr. David Sontag to its Strategic Advisory Board
CAMBRIDGE, Mass. – November 8, 2017– Leading precision medicine company GNS Healthcare (GNS) today announced the appointment of Dr. David Sontag to its Strategic Advisory Board (SAB). Dr. Sontag's research interests include machine learning and artificial intelligence...
read moreAI-Driven Discovery of Novel Predictors of Parkinson’s Disease Progression by GNS Healthcare Appears in The Lancet Neurology
Discovery May Accelerate the Development of New Drugs and Better Match New Drugs to Individual Patients
read moreGNS Healthcare and Swedish Cancer Institute Launch Machine Learning Collaboration to Strengthen Delivery of Precision Medicine in Breast Cancer Care
Causal Computer Models to Accelerate Work of Swedish Cancer Institute’s Molecular Tumor Board
read moreAmgen Ventures Invests in GNS Healthcare to Advance Applications of its REFS™ Causal Machine Learning and Simulation AI Platforms
CAMBRIDGE, Mass.– August 23, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced that it has raised an additional $6 million in equity from Amgen Ventures with participation from existing investor Alexandria Real Estate Equities. The...
read moreGNS Healthcare Licenses REFS™ Causal Machine Learning and Simulation Platform to Alexion to Accelerate Discovery of New Treatments for Rare Diseases
CAMBRIDGE, Mass. – August 10, 2017– GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to large and diverse data sets to better match drugs and other health interventions to individual patients, today announced...
read more